Woburn, Mass. – June 01, 2023 − Aphios Corporation announced today that it has been granted United States Patent No. 11,639,359 entitled “Bryoid Compositions, Methods of Making and Use Thereof,” May 02, 2023. The issued patent is part of a family of Aphios patents in the United States (Patent No. 10,954,248, Mar. 23, 2021), Europe (Patent No. 2,925,315, Jan. 16, 2019), Japan (Patent No. 6,440,628, Nov. 30, 2018), Hong Kong (Patent No. HK1,216,891, Nov. 22, 2019), and China (Patent No. ZL201380069328.2, Oct. 19, 2018).
Bryoids are a family of Bryostatins, such as Bryostatin-1, which are complex cyclic macrolide molecules. Bryoids were originally isolated from the marine bryozoan, Bugula neritina. Twenty-one Bryoid compositions, known as Bryostatins and numbered 1-22, not including the present novel Bryostatin, have been identified. According to Dr. Trevor P. Castor, President and CEO, Aphios Corporation, and inventor of this patent: “This Bryoid, Bryostatin-23 is a highly potent nanomolar activator of a-secretase activity in neuroblastoma cell models, being more effective than Bryostatin-1 in increasing activity of all PKC isoforms, particularly the novel PKC isoforms, delta and epsilon.”
Aphios is developing Bryoids as therapeutics for Central Nervous System (CNS) diseases such as Alzheimer’s disease, Multiple Sclerosis (MS), glaucoma, cancers and HIV-1 latency. For MS, Bryostatin-1 blocked the onset of neurologic deficits and reversed them after disease onset, even when administered in late-stage disease in a mouse model of the disease. Due to its potent remyelination effects, anti-inflammatory, anti-oxidant as well as its neuroprotective and neurogenic properties, Bryoids are an ideal multi-mechanism therapeutic choice for MS. increase the production of a neuronal enzyme, alpha-secretase (α-secretase), which cleaves the amyloid precursor protein into a soluble form inhibiting the formation of toxic, insoluble beta amyloid (Aβ) plaques that are associated with Alzheimer’s disease. In prostate cancer cells, Bryoids inhibit phorbol ester-induced apoptosis by differentially modulating protein kinase C delta (PKC-d) translocation and preventing PKC-d-mediated release of tumor necrosis factor-alpha (TNFα). In HIV-1 latency, Bryoids activate cellular transcription factors such as NF-κB (nuclear factor kappa of activated B-cells) that binds the HIV-1 promoter and regulates its transcriptional activity.
About Aphios Corporation:
Aphios (www.aphios.com) is a clinical stage, green biotechnology company developing enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, Aphios is developing enhanced therapeutics to prevent disease, maintain health, improve quality-of-life and treat chronic diseases including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19, and central and peripheral nervous system disorders in an environmentally sustainable manner.
Research reported in this press release was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R43AI165352. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.